Shares of Exelixis( EXEL) and partner Roche( RHHBY) are under pressure this morning after the companies announced that the Phase 3 IMblaze370 trial did not achieve statistical-significance on the primary efficacy endpoint evaluating the ability of a combination of a MEK inhibitor and anti-PD-L1 to improve overall survival in patients with microsatellite stable metastatic colorectal cancer.
Exelixis, Roche Slide After Colon Cancer Drug Fails To Meet Primary Study Goal
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться